Bio Rad Laboratories Stock Performance
| BIO Stock | USD 256.68 2.21 0.87% |
The firm shows a Beta (market volatility) of 0.94, which signifies possible diversification benefits within a given portfolio. Bio Rad returns are very sensitive to returns on the market. As the market goes up or down, Bio Rad is expected to follow. At this point, Bio Rad Laboratories has a negative expected return of -0.38%. Please make sure to confirm Bio Rad's accumulation distribution, and the relationship between the value at risk and day typical price , to decide if Bio Rad Laboratories performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Bio Rad Laboratories has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 0.87 | Five Day Return 0.99 | Year To Date Return (21.30) | Ten Year Return 90.16 | All Time Return 10 K |
Last Split Factor 2:1 | Last Split Date 2002-03-08 |
1 | Disposition of 279 shares by Andrew Last of Bio Rad at 4.6 subject to Rule 16b-3 | 01/23/2025 |
2 | Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO Investor Conference | 02/06/2025 |
3 | Disposition of 298 shares by Michael Crowley of Bio Rad at 4.6 subject to Rule 16b-3 | 02/14/2025 |
4 | BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of blue... | 02/25/2025 |
5 | 21 Billion Microfluidic Device Systems Market Analysis 2030 Tripling in Size from 2024 | 02/27/2025 |
6 | Staar Surgical, BD, Acutus Medical announce layoffs in Southern California | 02/28/2025 |
7 | Fisher Asset Management LLC Grows Stock Holdings in Bio-Rad Laboratories, Inc. | 03/03/2025 |
8 | Bio-Rad Laboratories Inc Trading 3.6 percent Higher on Mar 5 | 03/05/2025 |
9 | Japan In-Vitro Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, Danaher, Biomerieux, Roche, Becton, Sysmex, Bio-Rad Laborator... | 03/07/2025 |
10 | Proteomics Market Projected To Witness Substantial Growth, 2025-2032 Bio-Rad Laboratories, Inc., GE Healthcare, Bruker | 03/10/2025 |
11 | MTF Biologics Expands Partnership with Kolosis BIO to Strengthen DBX Brand | 03/12/2025 |
12 | Disposition of tradable shares by Allison Schwartz of Bio Rad at 4.6 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 404.4 M |
Bio |
Bio Rad Relative Risk vs. Return Landscape
If you would invest 32,836 in Bio Rad Laboratories on December 23, 2024 and sell it today you would lose (7,168) from holding Bio Rad Laboratories or give up 21.83% of portfolio value over 90 days. Bio Rad Laboratories is generating negative expected returns assuming volatility of 2.3249% on return distribution over 90 days investment horizon. In other words, 20% of stocks are less volatile than Bio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Bio Rad Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Rad's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio Rad Laboratories, and traders can use it to determine the average amount a Bio Rad's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1616
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIO |
Estimated Market Risk
| 2.32 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bio Rad is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Rad by adding Bio Rad to a well-diversified portfolio.
Bio Rad Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Rad, and Bio Rad fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | 0.0155 | ||||
| Profit Margin | (0.72) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 6.95 B | ||||
| Shares Outstanding | 22.94 M | ||||
| Price To Earning | 2.90 X | ||||
| Price To Book | 1.09 X | ||||
| Price To Sales | 2.82 X | ||||
| Revenue | 2.57 B | ||||
| Gross Profit | 1.38 B | ||||
| EBITDA | (2.14 B) | ||||
| Net Income | (99.4 M) | ||||
| Cash And Equivalents | 434.21 M | ||||
| Cash Per Share | 62.03 X | ||||
| Total Debt | 174.3 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.50 X | ||||
| Book Value Per Share | 234.53 X | ||||
| Cash Flow From Operations | 455.2 M | ||||
| Earnings Per Share | (65.35) X | ||||
| Market Capitalization | 7.24 B | ||||
| Total Asset | 9.36 B | ||||
| Retained Earnings | 7.42 B | ||||
| Working Capital | 2.56 B | ||||
| Current Asset | 466.61 M | ||||
| Current Liabilities | 208.93 M | ||||
About Bio Rad Performance
By examining Bio Rad's fundamental ratios, stakeholders can obtain critical insights into Bio Rad's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bio Rad is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 206.06 | 148.81 | |
| Return On Tangible Assets | (0.21) | (0.20) | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | (0.20) | (0.19) | |
| Return On Equity | (0.28) | (0.27) |
Things to note about Bio Rad Laboratories performance evaluation
Checking the ongoing alerts about Bio Rad for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio Rad Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio Rad Laboratories generated a negative expected return over the last 90 days | |
| The company reported the last year's revenue of 2.57 B. Reported Net Loss for the year was (99.4 M) with profit before taxes, overhead, and interest of 1.38 B. | |
| Bio Rad Laboratories has a poor financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: MTF Biologics Expands Partnership with Kolosis BIO to Strengthen DBX Brand |
- Analyzing Bio Rad's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Rad's stock is overvalued or undervalued compared to its peers.
- Examining Bio Rad's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Rad's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Rad's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio Rad's stock. These opinions can provide insight into Bio Rad's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (65.35) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.